Impact of the AT(2) Receptor Agonist C21 on Blood Pressure and Beyond

Sebastien Foulquier, U. Muscha Steckelings, Thomas Unger*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

52 Downloads (Pure)


It is now widely accepted that the angiotensin AT(2) receptor (AT(2)R) plays an important protective role during pathophysiologic conditions, acting as a repair system. The development of the first selective nonpeptide AT(2)R agonist C21 accelerated our understanding of AT(2)R-mediated protective signaling and actions. This article reviews the impact of C21 on blood pressure in normotensive and hypertensive animal models. Although C21 does not act as a classical antihypertensive drug, it could be useful in preventing hypertension-induced vascular and other end organ damages via anti-apoptotic, anti-fibrotic and anti-inflammatory actions. In particular, a strong body of evidence started to emerge around its anti-inflammatory feature. This property should be further investigated for potential clinical indications in cardiovascular diseases and beyond.
Original languageEnglish
Pages (from-to)403-409
JournalCurrent Hypertension Reports
Issue number5
Publication statusPublished - Oct 2012


  • Hypertension
  • Blood pressure
  • Angiotensin
  • AT(2)R
  • Renin-angiotensin system
  • RAS
  • Compound 21
  • C21
  • Inflammation
  • Antihypertensive drug therapy

Cite this